Barclays
BHVN

Barclays’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Barclays’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-218,095
Closed -$33M – 5646
2022
Q3 		$33M Buy
218,095
+107,352
+97% +$15.9M 0.04% 435
2022
Q2 		$16.1M Buy
110,743
+101,146
+1,054% +$12.9M 0.01% 810
2022
Q1 		$1.14M Sell
9,597
-58,008
-86% -$7.23M ﹤0.01% 2303
2021
Q4 		$9.32M Buy
67,605
+44,756
+196% +$5.69M ﹤0.01% 1305
2021
Q3 		$3.17M Buy
22,849
+14,335
+168% +$1.79M ﹤0.01% 1964
2021
Q2 		$826K Sell
8,514
-31,734
-79% -$2.58M ﹤0.01% 2784
2021
Q1 		$2.75M Sell
40,248
-79,389
-66% -$6.42M ﹤0.01% 2018
2020
Q4 		$10.3M Buy
119,637
+97,454
+439% +$8.26M 0.01% 1152
2020
Q3 		$1.44M Sell
22,183
-8,961
-29% -$587K ﹤0.01% 2377
2020
Q2 		$2.28M Sell
31,144
-168,260
-84% -$8.95M ﹤0.01% 2004
2020
Q1 		$6.79M Buy
199,404
+9,311
+5% +$426K 0.01% 1242
2019
Q4 		$10.3M Buy
190,093
+170,812
+886% +$8.46M 0.01% 1367
2019
Q3 		$804K Sell
19,281
-3,391
-15% -$143K ﹤0.01% 3859
2019
Q2 		$993K Sell
22,672
-42,873
-65% -$2.42M ﹤0.01% 3695
2019
Q1 		$3.37M Buy
65,545
+65,222
+20,193% +$2.82M ﹤0.01% 2024
2018
Q4 		$12K Sell
323
-12,784
-98% -$461K ﹤0.01% 6122
2018
Q3 		$492K Buy
13,107
+1,661
+15% +$61.1K ﹤0.01% 4296
2018
Q2 		$452K Sell
11,446
-35,505
-76% -$1.13M ﹤0.01% 4047
2018
Q1 		$1.21M Buy
46,951
+43,768
+1,375% +$1.31M ﹤0.01% 2989
2017
Q4 		$86K Buy
3,183
+1,741
+121% +$47.9K ﹤0.01% 5365
2017
Q3 		$54K Buy
1,442
+1,434
+17,925% +$43.5K ﹤0.01% 5319
2017
Q2 		$0 Buy
+8
New +$184 ﹤0.01% 7321

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

Barclays's BHVN Position: Q4 2022 in Review

Barclays sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 218,095 shares — an estimated $33M sold.

Barclays first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $33M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Barclays reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Barclays sold 218,095 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $33M.
  • Barclays first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • Barclays's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $33M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.